Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis

J Antimicrob Chemother. 2021 Feb 11;76(3):825-827. doi: 10.1093/jac/dkaa500.

Fritz Sörgel^{1

2}, Jakob J Malin^{3

4

5}, Henning Hagmann^{4

6}, Martina Kinzig¹, Muhammad Bilal⁷, Dennis A Eichenauer⁸, Oliver Scherf-Clavel^{1

9}, Alexander Simonis^{3

4}, Lobna El Tabei⁷, Uwe Fuhr⁷, Jan Rybniker^{3

4

5}

¹ IBMP - Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Straße 19, D-90562, Nürnberg-Heroldsberg, Germany.
² Institute of Pharmacology, West German Heart and Vascular Centre, University of Duisburg-Essen, Essen, Germany.
³ Department I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany.
⁴ Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
⁵ German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
⁶ Department II of Internal Medicine, University Hospital Cologne, Cologne, Germany.
⁷ Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
⁸ University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Intensive Care Program, Cologne, Germany.
⁹ University of Wuerzburg, Institute for Pharmacy and Food Chemistry, Wuerzburg, Germany.

No abstract available

Publication types